Year Founded
2012
Ownership
Private
Employees
~10
Stage
Preclinical
Modalities
Nanobody

Ossianix General Information

Developing single domain shark VNAR antibodies for enhanced delivery of therapeutics across the blood-brain barrier. TXP1 brain shuttle technology shows >30-fold improvement in brain delivery in primates.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Philadelphia, Pennsylvania
United States

Drug Pipeline

TXP1
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Ossianix's pipeline data

Book a demo

Key Partnerships

Lundbeck

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Ossianix Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Ossianix's complete valuation and funding history, request access »

Ossianix Investors

Lundbeck Pharmaceuticals
Investor Type: Venture Capital
Holding: Minority
BioAdvance
Investor Type: Venture Capital
Holding: Minority
The ALS Association
Investor Type: Venture Capital
Holding: Minority